This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the U.S. I am a U.S. resident I am a patient outside the U.S.
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Newly Diagnosed Patients
Imatinib-resistant/intolerant
Mechanism of Action
Dosing TASIGNA

DOSING TASIGNA

Clear dosing regimen that patients can incorporate into their everyday lives1

Choosing the correct dosage of TASIGNA for your patients is simple. TASIGNA capsules come in 2 strengths and in weekly dosing packs to help patients adhere to therapy.

For newly diagnosed patients1
Text for IE

Prescribe 300 mg (2 x 150-mg capsules) bid

300 mg for Newly Diagnosed TASIGNA Patients

For imatinib-resistant or -intolerant patients1

Prescribe 400 mg (2 x 200-mg capsules) bid

400 mg for Imatinib-Resistant or Intolerant Patients

TASIGNA is dispensed in convenient dosing packs

TASIGNA 150-mg Capsule Dosing Pack
  • 150-mg capsules are red and come in a box of 7 daily dosing packs
  • The daily dosing packs have been specially designed for patient convenience
    • Each blister pack contains 1 day’s dose
    • Morning and evening doses are perforated to allow separation
TASIGNA 200-mg Capsule Dosing Pack
  • 200-mg capsules are light yellow and come in a weekly dosing pack
  • Morning and evening doses for a full week are clearly identified
  • During 2011, the 200-mg capsules will switch over to a daily dosing blister pack similar to the current 150-mg packaging

You can help your patients adhere to TASIGNA

Studies with imatinib show that some physicians’ patients adhere better to oral Ph+ CML therapy than others.2 We’ve developed a few simple rules to help you explain how to appropriately take TASIGNA. Most patients already have a suitable window in their daily routine that is a perfect time to take their TASIGNA doses.

Tell your patients — choose a time to fight your Ph+ CML!1

With TASIGNA, just remember 12, 2, 1

TASIGNA 12,2,1 Dosing Schedule
  • 12: TASIGNA doses should be taken 12 hours apart with a glass of water
  • 2: Patients should fast for 2 hours before taking TASIGNA
  • 1: Patients should fast for 1 hour after taking TASIGNA

Use this interactive dosing questionnaire to create an individualized dosing guide for your patient, with examples of how other patients fit TASIGNA into their schedules.

Remind your patients — TASIGNA can interact with certain foods and drugs2

TASIGNA Food Interactions

Products or juices containing grapefruit, star fruit, and Seville oranges should be avoided during therapy.

TASIGNA Drug Interactions

It’s important that your patients keep you informed about all of the medications and over-the-counter supplements that they are taking. Remind them that they need to let you and any other doctors they visit know that they are taking TASIGNA before new medications are prescribed.

TASIGNA may interact with antiarrhythmics, strong inducers and inhibitors of CYP3A4, and CYP3A4 substrates including, but not limited to, the following:

  • Quinidine, amiodarone
  • Verapamil, diltiazem
  • Ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, erythromycin
  • Cyclosporine, tacrolimus — used as immunosuppressants
  • Ritonavir
  • Carbamazepine, phenobarbital, phenytoin
  • Rifampicin
  • St. John’s wort (also known as Hypericum perforatum)
  • Midazolam
  • Warfarin

References:
1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; December 2010.
2. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.

TASIGNA Interactive Game

The favorable tolerability profile of TASIGNA can help newly diagnosed patients maintain therapy.1

The distinct tolerability profile of TASIGNA in imatinib-resistant or -intolerant patients may help them maintain therapy.1